

# Andrea M Collins

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4356085/publications.pdf>

Version: 2024-02-01

45  
papers

8,172  
citations

331259

21  
h-index

344852

36  
g-index

53  
all docs

53  
docs citations

53  
times ranked

14019  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021, 397, 99-111.	6.3	3,887
2	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , 2021, 397, 881-891.	6.3	979
3	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 2032-2040.	15.2	900
4	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 1351-1362.	6.3	540
5	Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. <i>Lancet, The</i> , 2021, 398, 856-869.	6.3	430
6	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). <i>Lancet, The</i> , 2021, 398, 981-990.	6.3	214
7	Controlled Human Infection and Rechallenge with <i>Streptococcus pneumoniae</i> Reveals the Protective Efficacy of Carriage in Healthy Adults. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 855-864.	2.5	166
8	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. <i>Lancet, The</i> , 2022, 399, 36-49.	6.3	161
9	Experimental Human Pneumococcal Carriage Augments IL-17A-dependent T-cell Defence of the Lung. <i>PLoS Pathogens</i> , 2013, 9, e1003274.	2.1	85
10	First Human Challenge Testing of a Pneumococcal Vaccine. Double-Blind Randomized Controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 853-858.	2.5	81
11	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T <sub>H</sub> 1 response with a diverse TCR repertoire. <i>Science Translational Medicine</i> , 2021, 13, eabj7211.	5.8	80
12	Experimental Human Pneumococcal Carriage. <i>Journal of Visualized Experiments</i> , 2013, , .	0.2	64
13	Human Nasal Challenge with <i>Streptococcus pneumoniae</i> Is Immunising in the Absence of Carriage. <i>PLoS Pathogens</i> , 2012, 8, e1002622.	2.1	62
14	Saliva Alternative to Upper Respiratory Swabs for SARS-CoV-2 Diagnosis. <i>Emerging Infectious Diseases</i> , 2020, 26, 2769-2770.	2.0	59
15	Novel Analysis of Immune Cells from Nasal Microbiopsy Demonstrates Reliable, Reproducible Data for Immune Populations, and Superior Cytokine Detection Compared to Nasal Wash. <i>PLoS ONE</i> , 2017, 12, e0169805.	1.1	53
16	Polysaccharide-Specific Memory B Cells Predict Protection against Experimental Human Pneumococcal Carriage. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 1523-1531.	2.5	49
17	Innate and adaptive nasal mucosal immune responses following experimental human pneumococcal colonization. <i>Journal of Clinical Investigation</i> , 2019, 129, 4523-4538.	3.9	34
18	Nasal Pneumococcal Density Is Associated with Microaspiration and Heightened Human Alveolar Macrophage Responsiveness to Bacterial Pathogens. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 335-347.	2.5	33

#	ARTICLE	IF	CITATIONS
19	Streptococcus pneumoniae colonization associates with impaired adaptive immune responses against SARS-CoV-2. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	33
20	Pneumococcal Colonization in Healthy Adult Research Participants in the Conjugate Vaccine Era, United Kingdom, 2010–2017. <i>Journal of Infectious Diseases</i> , 2019, 219, 1989-1993.	1.9	28
21	Single use and conventional bronchoscopes for Broncho alveolar lavage (BAL) in research: a comparative study (NCT 02515591). <i>BMC Pulmonary Medicine</i> , 2017, 17, 83.	0.8	27
22	A Retrospective Evaluation of Critical Care Blood Culture Yield – Do Support Services Contribute to the “Weekend Effect?”. <i>PLoS ONE</i> , 2015, 10, e0141361.	1.1	24
23	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 1049-1060.	5.2	24
24	Protective effect of PCV vaccine against experimental pneumococcal challenge in adults is primarily mediated by controlling colonisation density. <i>Vaccine</i> , 2019, 37, 3953-3956.	1.7	20
25	Pneumococcal colonisation is an asymptomatic event in healthy adults using an experimental human colonisation model. <i>PLoS ONE</i> , 2020, 15, e0229558.	1.1	17
26	Experimental Human Pneumococcal Colonization in Older Adults Is Feasible and Safe, Not Immunogenic. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 604-613.	2.5	17
27	Pneumococcal colonization impairs mucosal immune responses to Live Attenuated Influenza Vaccine in adults. <i>JCI Insight</i> , 2021, 6, .	2.3	17
28	Safety and Immunogenicity Report from the Com-COV Study – a Single-Blind Randomised & Non-Inferiority Trial Comparing Heterologous & Homologous Prime-Boost Schedules with An Adenoviral Vected and mRNA COVID-19 Vaccine. <i>SSRN Electronic Journal</i> , 0, , .	0.4	14
29	Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	1.4	10
30	Increased IgG but normal IgA anti-pneumococcal protein antibodies in lung of HIV-infected adults. <i>Vaccine</i> , 2013, 31, 3469-3472.	1.7	8
31	Minimally Invasive Nasal Sampling in Children Offers Accurate Pneumococcal Colonization Detection. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 1147-1149.	1.1	7
32	Pneumococcal Colonization Rates in Patients Admitted to a United Kingdom Hospital with Lower Respiratory Tract Infection: a Prospective Case-Control Study. <i>Journal of Clinical Microbiology</i> , 2016, 54, 944-949.	1.8	6
33	CSF Levels of Elongation Factor Tu Is Associated With Increased Mortality in Malawian Adults With Streptococcus pneumoniae Meningitis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 603623.	1.8	5
34	Accuracy of the Mologic COVID-19 Rapid Antigen test: a prospective multi-centre analytical and clinical evaluation. <i>Wellcome Open Research</i> , 0, 6, 132.	0.9	5
35	Thirteen-Valent Pneumococcal Conjugate Vaccine – Induced Immunoglobulin G (IgG) Responses in Serum Associated With Serotype-Specific IgG in the Lung. <i>Journal of Infectious Diseases</i> , 2022, 225, 1626-1631.	1.9	5
36	Human Infection Challenge with Serotype 3 Pneumococcus. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 1379-1392.	2.5	5

#	ARTICLE	IF	CITATIONS
37	Anti-protein immunoglobulin M responses to pneumococcus are not associated with aging. <i>Pneumonia (Nathan Qld)</i> , 2018, 10, 5.	2.5	2
38	The nose is the best niche for detection of experimental pneumococcal colonisation in adults of all ages, using nasal wash. <i>Scientific Reports</i> , 2021, 11, 18279.	1.6	2
39	Influence of sex, season and environmental air quality on experimental human pneumococcal carriage acquisition: a retrospective cohort analysis. <i>ERJ Open Research</i> , 2022, 8, 00586-2021.	1.1	2
40	Title is missing!. , 2020, 15, e0229558.		0
41	Title is missing!. , 2020, 15, e0229558.		0
42	Title is missing!. , 2020, 15, e0229558.		0
43	Title is missing!. , 2020, 15, e0229558.		0
44	Title is missing!. , 2020, 15, e0229558.		0
45	Protocol for a phase IV double-blind randomised controlled trial to investigate the effect of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine on pneumococcal colonisation using the experimental human pneumococcal challenge model in healthy adults (PREVENTING PNEUMO 2). <i>BMI Open</i> , 2022, 12, e062109.	0.8	0